Rhinomed Limited advised investors that it has entered into a new distribution agreement with, and received an initial order for stock from a new retailer. These purchase orders confirm that Mute will be stocked on the shelves of an additional 3000 pharmacies across the USA. This agreement grows Rhinomeds' global store base to over 10,000 stores across three continents. There are limitations under the order arrangements on the disclosure that Rhinomed can currently provide to investors, as a guide it can provide the following information: Details regarding the identity of the retailer will be announced in line with stock appearing on shelf in the USA in July/August; the company has now received the initial opening order of 6000 units and expects more orders to follow; revenues from this new retail channel are not expected to impact the business until fiscal year 2019 second quarter at the earliest; the agreement has no fixed term and can be terminated by either party; Pricing details remain confidential. While the supplier agreement and receipt of an initial order creates potential new market opportunities for Rhinomed and increases the retail reach of the product in the USA it is not an assurance of ongoing or future retail sales. It is too early to accurately forecast the likely long term impact of revenues from the Agreement on Rhinomed financial results.